A typical oral dose of Zithromax consists of 500 mg for 1 day then 250 mg for 4 days. A typical intravenous dose consists of 500 mg for 2 days followed by 500 mg orally daily for an additional 5-8 days.
What Drugs, Substances, or Supplements Interact with Zithromax Injection?
hormonal birth control (such as pills, patch, or ring),
amiodarone,
disopyramide,
dofetilide,
dronedarone,
ibutilide,
pimozide,
procainamide,
quinidine, and
sotalol
Tell your doctor all medications and supplements you use.
Zithromax Injection During Pregnancy and Breastfeeding
Tell your doctor if you are pregnant or plan to become pregnant before using Zithromax; it is unknown if it will affect a fetus. Zithromax passes into breast milk. Consult your doctor before breastfeeding.
Additional Information
Our Zithromax Side Effects Drug Center provides a comprehensive view of available drug information on the potential side effects when taking this medication.
Zithromax Injection Consumer Information
SIDE EFFECTS: Nausea, vomiting, diarrhea/loose stools, stomach pain, or pain/redness at the injection site may occur. If any of these effects persist or worsen, tell your doctor or pharmacist promptly.
Remember that your doctor has prescribed this medication because he or she has judged that the benefit to you is greater than the risk of side effects. Many people using this medication do not have serious side effects.
Tell your doctor immediately if any of these unlikely but serious side effects occur: hearing changes (e.g., ringing in the ears, hearing loss), swelling legs/feet, eye problems (e.g., drooping eyelids, blurred vision), slurred speech, muscle weakness, persistent nausea/vomiting, severe abdominal/stomach pain, unusual weakness/tiredness, change in the amount of urine, dark urine, yellowing skin/eyes.
Use of this medication for prolonged or repeated periods may result in oral thrush or a new vaginal yeast infection. Contact your doctor if you notice white patches/sores in your mouth, a change in vaginal discharge, or other new symptoms.
Get medical help right away if any of these rare but serious side effects occur: severe dizziness, fainting, fast/irregular heartbeat.
This medication may rarely cause a severe intestinal condition (Clostridium difficile-associated diarrhea) due to a type of resistant bacteria. This condition may occur during treatment or weeks to months after treatment has stopped. Do not use anti-diarrhea products or narcotic pain medications if you have any of the following symptoms because these products may make them worse. Tell your doctor immediately if you develop: persistent diarrhea, abdominal or stomach pain/cramping, blood/mucus in your stool.
A very serious allergic reaction to this drug is rare. However, seek immediate medical attention if you notice any symptoms of a serious allergic reaction, including: rash, itching/swelling (especially of the face/tongue/throat), severe dizziness, trouble breathing.
An allergic reaction to this medication may return even if you stop the drug. If you have an allergic reaction, continue to watch for any of the above symptoms for several days after your last dose.
This is not a complete list of possible side effects. If you notice other effects not listed above, contact your doctor or pharmacist.
In the US -
Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088.
In Canada - Call your doctor for medical advice about side effects. You may report side effects to Health Canada at 1-866-234-2345.
Because clinical trials are
conducted under widely varying conditions, adverse reaction rates observed in
the clinical trials of a drug cannot be directly compared to rates in the
clinical trials of another drug and may not reflect the rates observed in
practice.
In clinical trials of
intravenous azithromycin for community-acquiredpneumonia, in which 2 to 5 IV doses
were given, the reported adverse reactions were mild to moderate in severity
and were reversible upon discontinuation of the drug. The majority of patients
in these trials had one or more comorbid diseases and were receiving
concomitant medications. Approximately 1.2% of the patients discontinued
intravenous ZITHROMAX therapy, and a total of 2.4% discontinued azithromycin
therapy by either the intravenous or oral route because of clinical or
laboratory side effects.
In clinical trials conducted in
patients with pelvic inflammatory disease, in which 1 to 2 IV doses were given,
2% of women who received monotherapy with azithromycin and 4% who received
azithromycin plus metronidazole discontinued therapy due to clinical side
effects.
Clinical adverse reactions
leading to discontinuations from these studies were gastrointestinal (abdominal
pain, nausea, vomiting, diarrhea), and rashes; laboratory side effects leading
to discontinuation were increases in transaminase levels and/or alkaline
phosphatase levels.
Overall, the most common adverse
reactions associated with treatment in adult patients who received IV/Oral
ZITHROMAX in studies of community-acquired pneumonia were related to the
gastrointestinal system with diarrhea/loose stools (4.3%), nausea (3.9%),
abdominal pain (2.7%), and vomiting (1.4%) being the most frequently reported.
Approximately 12% of patients
experienced a side effect related to the intravenous infusion; most common were
pain at the injection site (6.5%) and local inflammation (3.1%).
The most common adverse
reactions associated with treatment in adult women who received IV/Oral ZITHROMAX
in trials of pelvic inflammatory disease were related to the gastrointestinal
system. Diarrhea (8.5%) and nausea (6.6%) were most commonly reported, followed
by vaginitis (2.8%), abdominal pain (1.9%), anorexia (1.9%), rash and pruritus
(1.9%). When azithromycin was coadministered with metronidazole in these
trials, a higher proportion of women experienced adverse reactions of nausea
(10.3%), abdominal pain (3.7%), vomiting (2.8%), infusion site reaction,
stomatitis, dizziness, or dyspnea (all at 1.9%).
Adverse reactions that occurred
with a frequency of 1% or less included the following:
The following adverse reactions
have been identified during post-approval use of azithromycin. Because these
reactions are reported voluntarily from a population of uncertain size, it is
not always possible to reliably estimate their frequency or establish a causal
relationship to drug exposure.
Adverse reactions reported with
azithromycin during the post-marketing period in adult and/or pediatric patients
for which a causal relationship may not be established include:
When follow-up was provided,
changes in laboratory tests appeared to be reversible.
In multiple-dose clinical trials
involving more than 750 patients treated with ZITHROMAX (IV/Oral), less than 2%
of patients discontinued azithromycin therapy because of treatment-related
liver enzyme abnormalities.
&Copy; Zithromax Injection Patient Information is supplied by Cerner Multum, Inc. and Zithromax Injection Consumer information is supplied by First Databank, Inc., used under license and subject to their respective copyrights.
